Hera Biotech’s acquisition of HeraFem marks a pivotal advancement in the field of women’s health diagnostics, expanding its platform beyond endometriosis to tackle the global burden of cervical cancer. HeraFem, developed by Hera Diagnostics, is a breakthrough point-of-care diagnostic tool that combines electrical and optical spectroscopy with AI-powered analysis to detect cervical intraepithelial neoplasia grade 2 (CIN2+) and above with 91% sensitivity. Unlike traditional multi-step diagnostic methods that rely on sample collection and delayed lab results, HeraFem offers immediate, lab-independent diagnosis—ushering in a new era of real-time, non-invasive cervical cancer screening.

The device is engineered for use in both resource-rich and underserved healthcare settings, addressing key barriers in cervical cancer care such as cold chain dependency, pathology variability, and access to follow-up visits. Its ease of use, pain-free design, and ability to deliver same-visit results make it ideal for deployment in rural clinics, community health programs, and low-resource environments. The AI component continually improves with each scan, enhancing diagnostic accuracy over time and reinforcing the platform's ability to support clinicians with actionable, data-driven insights.

With cervical cancer claiming over 350,000 lives annually—most in low- and middle-income countries—HeraFem fills a critical need in global women’s health. Its integration into Hera Biotech’s broader diagnostic ecosystem not only elevates diagnostic precision and patient comfort but also accelerates equitable access to life-saving care. By simplifying screening and enabling earlier intervention, HeraFem positions Hera Biotech at the forefront of next-generation diagnostic innovation, committed to delivering scientific clarity and healthcare equity across continents.